The results showed that in the RT combined with camrelizumab group, camrelizumab effectively bound to PD-1 on CD8 T cells and competed directly with PD-L1 on tumor cells, thereby reducing the suppressive effect of tumor cells on immune cells. The gene discussed is CD274; the disease is neoplasm.